Aerie Pharmaceuticals Inc (NASDAQ:AERI) was the target of some unusual options trading on Tuesday. Investors acquired 2,536 call options on the stock. This represents an increase of approximately 1,456% compared to the average daily volume of 163 call options.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Truvestments Capital LLC purchased a new stake in shares of Aerie Pharmaceuticals during the first quarter valued at $33,000. Quantamental Technologies LLC purchased a new stake in Aerie Pharmaceuticals in the 1st quarter worth about $41,000. Oppenheimer Asset Management Inc. purchased a new stake in Aerie Pharmaceuticals in the 1st quarter worth about $47,000. Meeder Asset Management Inc. lifted its stake in Aerie Pharmaceuticals by 134.0% in the 1st quarter. Meeder Asset Management Inc. now owns 1,060 shares of the company’s stock worth $50,000 after acquiring an additional 607 shares in the last quarter. Finally, Amundi Pioneer Asset Management Inc. purchased a new stake in Aerie Pharmaceuticals in the 4th quarter worth about $105,000.

Shares of NASDAQ AERI opened at $24.02 on Thursday. Aerie Pharmaceuticals has a 12 month low of $23.12 and a 12 month high of $74.75. The stock has a market capitalization of $1.16 billion, a P/E ratio of -5.17 and a beta of 0.53. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.27 and a current ratio of 3.47. The company’s fifty day moving average is $30.81.

Aerie Pharmaceuticals (NASDAQ:AERI) last announced its earnings results on Tuesday, May 7th. The company reported ($0.78) EPS for the quarter, beating the consensus estimate of ($0.91) by $0.13. Aerie Pharmaceuticals had a negative return on equity of 93.96% and a negative net margin of 684.56%. The business had revenue of $10.85 million during the quarter, compared to the consensus estimate of $12.66 million. Research analysts anticipate that Aerie Pharmaceuticals will post -2.69 earnings per share for the current fiscal year.

Several analysts have recently weighed in on AERI shares. Needham & Company LLC cut their price objective on to $10.00 and set a “buy” rating for the company in a report on Wednesday, July 10th. Piper Jaffray Companies set a $76.00 price objective on Aerie Pharmaceuticals and gave the company a “buy” rating in a report on Friday, July 5th. BidaskClub lowered Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, June 26th. JMP Securities set a $58.00 price objective on Aerie Pharmaceuticals and gave the company an “outperform” rating in a report on Tuesday, July 2nd. Finally, ValuEngine lowered Zumiez from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd. Three analysts have rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $71.25.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Read More: Are all No-Load Funds Equal?

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.